Download - Chronic Myeloid Leukemia Hammad
-
8/10/2019 Chronic Myeloid Leukemia Hammad
1/33
AGHA MUHAMMAD HAMMAD KHANHOUSE OFFICER
ONCOLOGY (WARD- 4)
Chronic Myeloid Leukemia
-
8/10/2019 Chronic Myeloid Leukemia Hammad
2/33
Hem atop o iet ic Prog eni to rs
-
8/10/2019 Chronic Myeloid Leukemia Hammad
3/33
Leukemias:What are Leukemias?
Neoplasm of white blood cell and itsprecursor.Clonal proliferations andaccumulation of cells in marrow.Classify as:
Acute leukemiasChronic leukemias
-
8/10/2019 Chronic Myeloid Leukemia Hammad
4/33
Types of Leukemia
Acute : NoMaturation beyondblast
Chronic :Maturation beyondblast
Lymphocytic (B or Tlineage) ALL CLLMyeloid granulocytesErythroidsMonocytesPlatelets
AML CML
-
8/10/2019 Chronic Myeloid Leukemia Hammad
5/33
What is CML ?Chronic Myelogenous Leukemia (CML) isdefined as,
a malignant cancer of the bone marrow.
It causes rapid growth of the blood-forming cells (known as myeloidprecursors) in the bone marrow, peripheral
blood, and body tissues.
-
8/10/2019 Chronic Myeloid Leukemia Hammad
6/33
Epidemiology of CML Approximately 5,050 cases in the U.S. in 2009 (11%of all leukemias) with an incidence that increases
significantly with age (median age ~ 55)
Risk Factors include:
prior high dose radiation exposure exposure to certain organic solvents (benzene) age gender (male > female)
A very small percentage (< 0.1%) of individuals canexpress Bcr-Abl but not develop CML (wrong cellof origin, multiple genetic mutations leading tonon-viability, immune surveillance)
-
8/10/2019 Chronic Myeloid Leukemia Hammad
7/33
CML Pathophysiology the Philadelphia Chromosome
CML was the firstmalignancy to be linkedto a clear geneticabnormality, thechromosomaltranslocation known asthe Philadelphiachromosome . This
chromosomalabnormality is sonamed because it wasfirst discovered anddescribed in 1960
-
8/10/2019 Chronic Myeloid Leukemia Hammad
8/33
-
8/10/2019 Chronic Myeloid Leukemia Hammad
9/33
DIAGNOSIS
-
8/10/2019 Chronic Myeloid Leukemia Hammad
10/33
CML Peripheral Blood and BMFindings
Peripheral smear canonly give a presumptive
1) leukocytosis with aleft shift 2) normocytic anemia. 3) thrombocytosis in50% of pts. 4) absoluteeosinophilia with anormal % of Eos. 5) absolute and relative
increase in basophils
-
8/10/2019 Chronic Myeloid Leukemia Hammad
11/33
Bone marrowBone marrow
Hypercellular(reduced fatspaces).Myeloid:erythroidratio 10:1 to 30:1(N : 2:1).Myelocytepredominant cell,blasts less 10%.Megakaryocytesincreased &dysplastic.Increase reticulinfibrosis in 30-40%.
-
8/10/2019 Chronic Myeloid Leukemia Hammad
12/33
Diagnosing Chronic Myeloid
Leukemia
Karyotyping in CML : ( 1-10%).
Fluorescence in-situ hybridization(FISH): ( 0.5-5%).
Quantitative RT-PCR for Bcr-Abl: ( 0.0001-0.001%)
-
8/10/2019 Chronic Myeloid Leukemia Hammad
13/33
Diagnostic Criteria for the 3Phases of the Disease
Patients who have CML are said to be in one ofthe following three phases (in order ofoccurrence):
the chronic phase (between 1 and 15%blasts) the accelerated phase (between 15% - 30%blasts) the blast phase (more than 30% blasts).
-
8/10/2019 Chronic Myeloid Leukemia Hammad
14/33
PHASES
-
8/10/2019 Chronic Myeloid Leukemia Hammad
15/33
Chronic phase 85% of patients with CML are in the chronic
phase at the time of diagnosis. Asymptomatic or have only mild symptomsof fatigue, left side pain, joint and/or hippain, or abdominal fullness. myleoblast cell
-
8/10/2019 Chronic Myeloid Leukemia Hammad
16/33
Accelerated phase Median duration is 3.5 5 yrs beforeevolving to more aggressive phases.Clinical features
Increasing splenomegaly refractory tochemoIncreasing chemotherapy requirement
Lab features: (WHO CRITERIA)1. 10 19% myeloblasts in the blood or bone
marrow.2. >20% basophils in the blood or bone marrow.
3. Platelet count 1,000,000, unresponsive to
therapy.5. Cytogenetic evolution with new
abnormalities in addition to the Philadelphia
-
8/10/2019 Chronic Myeloid Leukemia Hammad
17/33
Blastic PhaseResembles acute leukaemia.Diagnosis requires > 30% blast in
Large clusters of blasts in the bonemarrow on biopsy .Development of a chloroma (solidfocus of leukemia outside the bonemarrow).
-
8/10/2019 Chronic Myeloid Leukemia Hammad
18/33
Discussion with family The disease & diagnosis
Prognosis Choices of treatment
General Management
-
8/10/2019 Chronic Myeloid Leukemia Hammad
19/33
CML - principles of treatment1. Relieve symptoms of
hyperleukocytosis, splenomegaly andthrombocytosis.
HydrationChemotherapy (bulsuphan,Hydoxyurea)
2. Control and prolong chronic phase(non-curative).alpha interferon+chemotherapyImatinib mesylateChemotherapy (hydroxyurea)
-
8/10/2019 Chronic Myeloid Leukemia Hammad
20/33
CML - principles of treatment
3) Eradicate malignant clone(curative).
Allogeneic transplantationImatinib mesylate/STI 571(Thyrosine kinase inhibitor)
-
8/10/2019 Chronic Myeloid Leukemia Hammad
21/33
Treatment Milestones for CML Definitions of Responses to Treatments Hematologic Response Complete Hematologic response 1) Normal PB counts (WBC < 10 and plt < 450) 2) Normal WBC differential 3) No Dz symptoms 4) Normalization of the size of the liver and spleenCytogenetic Responses : Ph + Metaphases 1) complete: 0% 2) partial: 1% - 35% 3) minor: 36% - 65%
4) minimal: 66% - 95% 5) none: 96% - 100%Molecular Responses: ratio of Bcr-Abl/Abl Major Molecular Response 3-log 10 reduction from initial diagnosis sample (i.e. 25 0.025)
-
8/10/2019 Chronic Myeloid Leukemia Hammad
22/33
ChemotherapyBusulphan
Alkylating agentPreferred in older pts (not candidate
for transplant)Side effect :prolonged myelosuppressionPulmonary fibrosisSkin pigmentationinfertility
-
8/10/2019 Chronic Myeloid Leukemia Hammad
23/33
ChemotherapyHydoxyures
Fewer side effectActs by inhibiting the enzyme
ribonucleotide reductaseHaematological remissions obtain in80% for both drugsHowever disease progression notaltered and persistence of Phchromosome containing clone
-
8/10/2019 Chronic Myeloid Leukemia Hammad
24/33
ChemotherapyRecombinant human - Interferon
Prolong chronic phase and increasesurvival
Haematogical and cytogeneticremissionSide effect
Flu like symptomsFever and chillsAnorexiaDepression
-
8/10/2019 Chronic Myeloid Leukemia Hammad
25/33
Imatinib Mesylate:Mechanism of Action
Imatinib mesylate occupies the ATPbinding pocket of the Abl kinase domainThis prevents substrate phosphorylation
and signalingA lack of signaling inhibits proliferationand survival
-
8/10/2019 Chronic Myeloid Leukemia Hammad
26/33
Imatinib has Revolutionizedthe Treatment of CML IRIS Trial
-
8/10/2019 Chronic Myeloid Leukemia Hammad
27/33
Imatinib Mesylate in ChronicPhase CML Following IFN- Failure: Overall Survival*
Seventy-five percent of patients remain alive
on imatinib mesylate therapy after a medianfollow-up of 45 months .Patients who received imatinib mesylate hadsignificantly improved survival rates , with anestimated 4-year survival rate of 86% vs 43%(P
-
8/10/2019 Chronic Myeloid Leukemia Hammad
28/33
Treatment Options for ResistantDisease1) Dose Escalation of imatinib
2) Second Generation TKIs
3) Bone Marrow Transplant
-
8/10/2019 Chronic Myeloid Leukemia Hammad
29/33
Dose Escalation of imatinibSTART-R Trial Patients resistant to 400mg-600 mg of imaitnib weretreated with either 70 mg BID of dasatinib or 800 mg of
imaitnib primary endpoint of the trial was the rate of
MCyR(major cytogenetic response )at 12 weeks andthis was equal
(D=36%; IM=29%; p = .40)
At a minimum follow-up of 2 years, dasatinibdemonstrated higher rates of: complete hematologic response (93% vs 82%; P
= .034) major cytogenetic response (MCyR) (53% vs
33%; P = .017) complete cytogenetic response (44% vs 18%; P =
.0025)
The depth of the previous response to imatinib may beassociated with the proportion of patients respondingto dose escalation. Patients having achieved a priormajor cytogenetic response (MCyR) with imatinibreported a greater than 50% chance of reachieving thatresponse with high-dose imaitnib, yet only 7% of
-
8/10/2019 Chronic Myeloid Leukemia Hammad
30/33
Second GenerationTyrosine Kinase Inhibitors (TKIs) The FDA has approved 2 additional oral TKIs for the treatment
ofimatinib relapsed/refractory or imatinib intolerant CML
1. Dasatinib
2. Nilotinib
-
8/10/2019 Chronic Myeloid Leukemia Hammad
31/33
Bone Marrow TransplantationAllogeneic bone marrow transplant remains the onlyknown curative option in CML
Associated with an increased morbidity and mortality.
Therefore, not typically applied for upfront therapy forCML considered only in cases of matched-related
extremely young pts (pediatrics)
However, often considered in those withrelapsed/refractory disease to TKI based therapies efficacy of the transplant dependent upon the
phase of the disease at the time of thetransplant: CP>AP>BP
-
8/10/2019 Chronic Myeloid Leukemia Hammad
32/33
CML - prognosisMedian survival 3.5 yrs (range 2-8 yrs).Interferon + chemotherapy :6 years.Transplant : 5+ years.
Imatinib mesylate : 8.9 years.(5yr: 86%;10yr:68%).
-
8/10/2019 Chronic Myeloid Leukemia Hammad
33/33
THANK YOU